JP2015503618A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015503618A5 JP2015503618A5 JP2014552290A JP2014552290A JP2015503618A5 JP 2015503618 A5 JP2015503618 A5 JP 2015503618A5 JP 2014552290 A JP2014552290 A JP 2014552290A JP 2014552290 A JP2014552290 A JP 2014552290A JP 2015503618 A5 JP2015503618 A5 JP 2015503618A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- disease
- formula
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 60
- 150000001875 compounds Chemical class 0.000 claims description 50
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 34
- 229910052757 nitrogen Inorganic materials 0.000 claims description 24
- 208000035475 disorder Diseases 0.000 claims description 22
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 20
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 20
- 125000005842 heteroatom Chemical group 0.000 claims description 20
- 229910052760 oxygen Inorganic materials 0.000 claims description 20
- 239000001301 oxygen Chemical group 0.000 claims description 20
- 229910052717 sulfur Chemical group 0.000 claims description 20
- 239000011593 sulfur Chemical group 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 claims description 14
- 101710199015 Interleukin-1 receptor-associated kinase 1 Proteins 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- 229920006395 saturated elastomer Polymers 0.000 claims description 14
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 13
- 230000001684 chronic effect Effects 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- 206010020751 Hypersensitivity Diseases 0.000 claims description 8
- 206010025323 Lymphomas Diseases 0.000 claims description 8
- 230000001363 autoimmune Effects 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 206010010741 Conjunctivitis Diseases 0.000 claims description 6
- 201000005569 Gout Diseases 0.000 claims description 6
- 208000034578 Multiple myelomas Diseases 0.000 claims description 6
- 201000002481 Myositis Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims description 6
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 6
- 125000001931 aliphatic group Chemical group 0.000 claims description 6
- 208000026935 allergic disease Diseases 0.000 claims description 6
- 230000007815 allergy Effects 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 6
- 125000002837 carbocyclic group Chemical group 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 4
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 208000015943 Coeliac disease Diseases 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 108010002352 Interleukin-1 Proteins 0.000 claims description 4
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 4
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 4
- 201000009906 Meningitis Diseases 0.000 claims description 4
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 claims description 4
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 claims description 4
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 208000005141 Otitis Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 206010033645 Pancreatitis Diseases 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 4
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 4
- 206010039710 Scleroderma Diseases 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 206010046851 Uveitis Diseases 0.000 claims description 4
- 206010047115 Vasculitis Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 125000002619 bicyclic group Chemical group 0.000 claims description 4
- 206010006451 bronchitis Diseases 0.000 claims description 4
- 208000019258 ear infection Diseases 0.000 claims description 4
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 4
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims description 4
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 4
- 206010023332 keratitis Diseases 0.000 claims description 4
- 201000010666 keratoconjunctivitis Diseases 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 206010028417 myasthenia gravis Diseases 0.000 claims description 4
- 230000009826 neoplastic cell growth Effects 0.000 claims description 4
- 201000008383 nephritis Diseases 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 208000001297 phlebitis Diseases 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 239000012472 biological sample Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 208000003200 Adenoma Diseases 0.000 claims description 2
- 206010001233 Adenoma benign Diseases 0.000 claims description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 2
- 206010001889 Alveolitis Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 2
- 241000272517 Anseriformes Species 0.000 claims description 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 2
- 206010003011 Appendicitis Diseases 0.000 claims description 2
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims description 2
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
- 208000020084 Bone disease Diseases 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 claims description 2
- 206010006448 Bronchiolitis Diseases 0.000 claims description 2
- 208000023611 Burkitt leukaemia Diseases 0.000 claims description 2
- 206010006811 Bursitis Diseases 0.000 claims description 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 2
- 208000006029 Cardiomegaly Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 208000002177 Cataract Diseases 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 2
- 206010048832 Colon adenoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010057254 Connective tissue inflammation Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 2
- 206010061818 Disease progression Diseases 0.000 claims description 2
- 241001317099 Dystaxia Species 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 208000004145 Endometritis Diseases 0.000 claims description 2
- 208000004232 Enteritis Diseases 0.000 claims description 2
- 206010014950 Eosinophilia Diseases 0.000 claims description 2
- 206010015218 Erythema multiforme Diseases 0.000 claims description 2
- 206010016228 Fasciitis Diseases 0.000 claims description 2
- 208000001362 Fetal Growth Retardation Diseases 0.000 claims description 2
- 206010016717 Fistula Diseases 0.000 claims description 2
- 206010070531 Foetal growth restriction Diseases 0.000 claims description 2
- 206010061968 Gastric neoplasm Diseases 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 208000005577 Gastroenteritis Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 208000022461 Glomerular disease Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 206010018634 Gouty Arthritis Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 206010019755 Hepatitis chronic active Diseases 0.000 claims description 2
- 206010062639 Herpes dermatitis Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 2
- 206010021143 Hypoxia Diseases 0.000 claims description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 claims description 2
- 101710199010 Interleukin-1 receptor-associated kinase 4 Proteins 0.000 claims description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- 201000008197 Laryngitis Diseases 0.000 claims description 2
- 206010024238 Leptospirosis Diseases 0.000 claims description 2
- 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 claims description 2
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 claims description 2
- 208000004883 Lipoid Nephrosis Diseases 0.000 claims description 2
- 208000004852 Lung Injury Diseases 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 206010028289 Muscle atrophy Diseases 0.000 claims description 2
- 208000003926 Myelitis Diseases 0.000 claims description 2
- 208000009525 Myocarditis Diseases 0.000 claims description 2
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims description 2
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010029350 Neurotoxicity Diseases 0.000 claims description 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 2
- 206010031252 Osteomyelitis Diseases 0.000 claims description 2
- 208000027868 Paget disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 206010034038 Parotitis Diseases 0.000 claims description 2
- 206010034277 Pemphigoid Diseases 0.000 claims description 2
- 201000011152 Pemphigus Diseases 0.000 claims description 2
- 241000721454 Pemphigus Species 0.000 claims description 2
- 201000007100 Pharyngitis Diseases 0.000 claims description 2
- 208000007452 Plasmacytoma Diseases 0.000 claims description 2
- 206010035742 Pneumonitis Diseases 0.000 claims description 2
- 206010065159 Polychondritis Diseases 0.000 claims description 2
- 206010036105 Polyneuropathy Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
- 208000028561 Primary cutaneous T-cell lymphoma Diseases 0.000 claims description 2
- 206010036774 Proctitis Diseases 0.000 claims description 2
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 claims description 2
- 206010037549 Purpura Diseases 0.000 claims description 2
- 241001672981 Purpura Species 0.000 claims description 2
- 206010037596 Pyelonephritis Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 201000010208 Seminoma Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 230000006044 T cell activation Effects 0.000 claims description 2
- 206010042970 T-cell chronic lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 claims description 2
- 208000000491 Tendinopathy Diseases 0.000 claims description 2
- 206010043255 Tendonitis Diseases 0.000 claims description 2
- 208000004760 Tenosynovitis Diseases 0.000 claims description 2
- 108090000190 Thrombin Proteins 0.000 claims description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 208000024780 Urticaria Diseases 0.000 claims description 2
- 208000006374 Uterine Cervicitis Diseases 0.000 claims description 2
- 206010046914 Vaginal infection Diseases 0.000 claims description 2
- 201000008100 Vaginitis Diseases 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 206010000269 abscess Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 206010069351 acute lung injury Diseases 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 210000004100 adrenal gland Anatomy 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims description 2
- 208000037883 airway inflammation Diseases 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 208000004631 alopecia areata Diseases 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 230000036783 anaphylactic response Effects 0.000 claims description 2
- 208000003455 anaphylaxis Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 2
- 208000010217 blepharitis Diseases 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 230000001925 catabolic effect Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 230000030833 cell death Effects 0.000 claims description 2
- 208000015114 central nervous system disease Diseases 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 206010008323 cervicitis Diseases 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 208000003167 cholangitis Diseases 0.000 claims description 2
- 201000001352 cholecystitis Diseases 0.000 claims description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 208000027710 cyclic fever Diseases 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 201000003146 cystitis Diseases 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 230000001066 destructive effect Effects 0.000 claims description 2
- 229910052805 deuterium Inorganic materials 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 2
- 230000005750 disease progression Effects 0.000 claims description 2
- 208000007784 diverticulitis Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000002169 ectodermal dysplasia Diseases 0.000 claims description 2
- 208000031068 ectodermal dysplasia syndrome Diseases 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 206010014665 endocarditis Diseases 0.000 claims description 2
- 230000002124 endocrine Effects 0.000 claims description 2
- 208000010227 enterocolitis Diseases 0.000 claims description 2
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 claims description 2
- 210000000918 epididymis Anatomy 0.000 claims description 2
- 201000010063 epididymitis Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 230000002449 erythroblastic effect Effects 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 208000030941 fetal growth restriction Diseases 0.000 claims description 2
- 230000003890 fistula Effects 0.000 claims description 2
- 230000003325 follicular Effects 0.000 claims description 2
- 208000016361 genetic disease Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 231100000852 glomerular disease Toxicity 0.000 claims description 2
- 229930195712 glutamate Natural products 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 208000014951 hematologic disease Diseases 0.000 claims description 2
- 208000007475 hemolytic anemia Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 210000004276 hyalin Anatomy 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 206010020718 hyperplasia Diseases 0.000 claims description 2
- 230000009610 hypersensitivity Effects 0.000 claims description 2
- 201000006362 hypersensitivity vasculitis Diseases 0.000 claims description 2
- 230000007954 hypoxia Effects 0.000 claims description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims description 2
- 201000008319 inclusion body myositis Diseases 0.000 claims description 2
- 208000015266 indolent plasma cell myeloma Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 208000003849 large cell carcinoma Diseases 0.000 claims description 2
- 210000000867 larynx Anatomy 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000011486 lichen planus Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 231100000515 lung injury Toxicity 0.000 claims description 2
- 208000027202 mammary Paget disease Diseases 0.000 claims description 2
- 208000004396 mastitis Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 201000000585 muscular atrophy Diseases 0.000 claims description 2
- 231100000228 neurotoxicity Toxicity 0.000 claims description 2
- 230000007135 neurotoxicity Effects 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 206010057056 paraneoplastic pemphigus Diseases 0.000 claims description 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 2
- 208000008494 pericarditis Diseases 0.000 claims description 2
- 230000000737 periodic effect Effects 0.000 claims description 2
- 201000001245 periodontitis Diseases 0.000 claims description 2
- 206010034674 peritonitis Diseases 0.000 claims description 2
- 210000004180 plasmocyte Anatomy 0.000 claims description 2
- 208000008423 pleurisy Diseases 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 230000007824 polyneuropathy Effects 0.000 claims description 2
- 201000007094 prostatitis Diseases 0.000 claims description 2
- 230000001185 psoriatic effect Effects 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- 210000000664 rectum Anatomy 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 238000007634 remodeling Methods 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 230000003393 splenic effect Effects 0.000 claims description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 208000003265 stomatitis Diseases 0.000 claims description 2
- 210000004243 sweat Anatomy 0.000 claims description 2
- 210000000106 sweat gland Anatomy 0.000 claims description 2
- 201000004595 synovitis Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 201000004415 tendinitis Diseases 0.000 claims description 2
- 210000001550 testis Anatomy 0.000 claims description 2
- 229960004072 thrombin Drugs 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 206010043778 thyroiditis Diseases 0.000 claims description 2
- 206010044008 tonsillitis Diseases 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 208000024719 uterine cervix neoplasm Diseases 0.000 claims description 2
- 210000001215 vagina Anatomy 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 208000002003 vulvitis Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 12
- 230000000172 allergic effect Effects 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 claims 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 claims 1
- 239000013610 patient sample Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 13
- 0 CCc1ncnc2c1c(C(CC(C=*)C(*)=O)CC1)c1[s]2 Chemical compound CCc1ncnc2c1c(C(CC(C=*)C(*)=O)CC1)c1[s]2 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261585194P | 2012-01-10 | 2012-01-10 | |
| US61/585,194 | 2012-01-10 | ||
| US201261663227P | 2012-06-22 | 2012-06-22 | |
| US61/663,227 | 2012-06-22 | ||
| US201261682637P | 2012-08-13 | 2012-08-13 | |
| US61/682,637 | 2012-08-13 | ||
| US201261724695P | 2012-11-09 | 2012-11-09 | |
| US61/724,695 | 2012-11-09 | ||
| US201261734133P | 2012-12-06 | 2012-12-06 | |
| US61/734,133 | 2012-12-06 | ||
| PCT/US2013/020981 WO2013106535A1 (en) | 2012-01-10 | 2013-01-10 | Irak inhibitors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016203006A Division JP2017008110A (ja) | 2012-01-10 | 2016-10-14 | Ｉｒａｋ阻害剤およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015503618A JP2015503618A (ja) | 2015-02-02 |
| JP2015503618A5 true JP2015503618A5 (enExample) | 2016-02-18 |
| JP6126131B2 JP6126131B2 (ja) | 2017-05-10 |
Family
ID=48781892
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014552290A Active JP6126131B2 (ja) | 2012-01-10 | 2013-01-10 | Ｉｒａｋ阻害剤およびその使用 |
| JP2016203006A Pending JP2017008110A (ja) | 2012-01-10 | 2016-10-14 | Ｉｒａｋ阻害剤およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016203006A Pending JP2017008110A (ja) | 2012-01-10 | 2016-10-14 | Ｉｒａｋ阻害剤およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9212190B2 (enExample) |
| EP (1) | EP2802330A4 (enExample) |
| JP (2) | JP6126131B2 (enExample) |
| CN (1) | CN104582705A (enExample) |
| AU (2) | AU2013207972B2 (enExample) |
| BR (1) | BR112014017021A8 (enExample) |
| CA (1) | CA2863259A1 (enExample) |
| HK (1) | HK1209632A1 (enExample) |
| TW (2) | TW201728592A (enExample) |
| WO (1) | WO2013106535A1 (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ717373A (en) | 2010-06-03 | 2017-11-24 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
| AU2011281015B2 (en) | 2010-07-23 | 2015-09-24 | President And Fellows Of Harvard College | Tricyclic proteasome activity enhancing compounds |
| EP3239154A1 (en) | 2011-01-10 | 2017-11-01 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| WO2013106535A1 (en) | 2012-01-10 | 2013-07-18 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| JP2015513317A (ja) * | 2012-01-25 | 2015-05-07 | プロテオステイシス セラピューティクス，インコーポレイテッド | プロテアソーム活性を増強する化合物 |
| CA2861464C (en) * | 2012-01-25 | 2018-03-06 | Proteostasis Therapeutics, Inc. | Proteasome activity modulating tricyclic compounds |
| JP2015528801A (ja) | 2012-07-11 | 2015-10-01 | ニンバス アイリス， インコーポレイテッド | Ｉｒａｋ阻害剤およびその使用 |
| EP2872144A4 (en) | 2012-07-11 | 2015-12-02 | Nimbus Iris Inc | IRAQ INHIBITOR AND USES THEREOF |
| US10954567B2 (en) | 2012-07-24 | 2021-03-23 | Pharmacyclics Llc | Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK) |
| HK1216859A1 (zh) | 2013-01-10 | 2016-12-09 | Nimbus Iris, Inc. | Irak抑制劑和其用途 |
| US8778365B1 (en) | 2013-01-31 | 2014-07-15 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
| EP2951187A1 (en) | 2013-02-01 | 2015-12-09 | Bayer Pharma Aktiengesellschaft | Substituted thienopyrimidines and pharmaceutical use thereof |
| PE20161035A1 (es) | 2013-03-15 | 2016-11-13 | Global Blood Therapeutics Inc | Compuestos y usos de estos para la modulacion de la hemoglobina |
| WO2014194245A2 (en) * | 2013-05-31 | 2014-12-04 | Nimbus Iris, Inc. | Cdk8 inhibitors and uses thereof |
| WO2014194242A2 (en) * | 2013-05-31 | 2014-12-04 | Nimbus Iris, Inc. | Flt3 inhibitors and uses thereof |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| CA2925211A1 (en) * | 2013-09-27 | 2015-04-02 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| TW201605867A (zh) * | 2013-11-20 | 2016-02-16 | 拜耳製藥公司 | 噻吩并嘧啶 |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| CA2942528A1 (en) | 2014-03-20 | 2015-09-24 | Pharmacyclics Inc. | Phospholipase c gamma 2 and resistance associated mutations |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US20160008366A1 (en) * | 2014-07-14 | 2016-01-14 | Pharmacyclics Llc | Btk inhibitors for the treatment of cns malignancies |
| RS59707B1 (sr) | 2014-10-24 | 2020-01-31 | Bristol Myers Squibb Co | Derivati karbazola |
| JP2016124791A (ja) * | 2014-12-26 | 2016-07-11 | 国立大学法人 千葉大学 | 新規化合物及びこれを有効成分とする抗ウイルス剤 |
| CN104592248A (zh) * | 2014-12-31 | 2015-05-06 | 芜湖杨燕制药有限公司 | 一种4-氯-6-取代噻吩并[2,3-d]嘧啶化合物的制备方法 |
| CA2980800C (en) | 2015-04-22 | 2023-10-31 | Rigel Pharmaceuticals, Inc. | Pyrazole compounds and method for making and using the compounds |
| JP6994454B2 (ja) * | 2015-08-04 | 2022-01-14 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ベンズアゾール化合物ならびに該化合物の作製方法および使用方法 |
| SG10201508795XA (en) * | 2015-10-23 | 2017-05-30 | Agency Science Tech & Res | Method for treating cancer |
| US11254667B2 (en) | 2016-08-17 | 2022-02-22 | Children's Hospital Medical Center | Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors |
| US11542261B2 (en) | 2016-08-17 | 2023-01-03 | Children's Hospital Medical Center | Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors |
| US20210292843A1 (en) * | 2016-10-28 | 2021-09-23 | Children's Hospital Medical Center | Treatment of diseases associated with activated irak |
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| WO2019001461A1 (zh) * | 2017-06-27 | 2019-01-03 | 南京明德新药研发股份有限公司 | Irak4抑制剂 |
| EP3684366A4 (en) | 2017-09-22 | 2021-09-08 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES OF THE LATEST |
| EP3684365A4 (en) | 2017-09-22 | 2021-09-08 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND USES OF SUCH |
| WO2019099926A1 (en) | 2017-11-17 | 2019-05-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| CN108033931B (zh) * | 2017-12-28 | 2020-03-10 | 山东铂源药业有限公司 | 一种N-Boc哌嗪的合成方法 |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| EP3737675A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
| EP3817822A4 (en) | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
| TWI898556B (zh) | 2018-07-13 | 2025-09-21 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒衍生物 |
| DK3823623T3 (da) * | 2018-07-20 | 2025-01-02 | Merck Patent Gmbh | Substitueret amino-pyrimidinforbindelse til anvendelse i en fremgangsmåde til behandling og forebyggelse af multipel sklerose |
| WO2020041331A1 (en) | 2018-08-20 | 2020-02-27 | Arvinas Operations, Inc. | Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases |
| SG11202105424PA (en) | 2018-11-30 | 2021-06-29 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| CA3116141C (en) | 2018-12-06 | 2023-09-05 | Daiichi Sankyo Company, Limited | Cycloalkane-1,3-diamine derivative |
| CN113874015B (zh) | 2018-12-21 | 2024-05-24 | 细胞基因公司 | Ripk2的噻吩并吡啶抑制剂 |
| WO2020264499A1 (en) * | 2019-06-28 | 2020-12-30 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| US11370787B2 (en) | 2019-08-30 | 2022-06-28 | Rigel Pharmaceuticals, Inc. | Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations |
| EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
| MX2022007576A (es) | 2019-12-17 | 2022-09-23 | Kymera Therapeutics Inc | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| EP4259128A4 (en) * | 2020-12-09 | 2025-04-30 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| AU2021413371A1 (en) | 2020-12-30 | 2023-07-13 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| AU2022220043A1 (en) | 2021-02-15 | 2023-08-31 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| US12357623B2 (en) | 2021-03-03 | 2025-07-15 | Rigel Pharmaceuticals, Inc. | Method for treating a disease or condition using a pyrazole compound or formulation thereof |
| US12097261B2 (en) | 2021-05-07 | 2024-09-24 | Kymera Therapeutics, Inc. | CDK2 degraders and uses thereof |
| CN118302168A (zh) | 2021-10-29 | 2024-07-05 | 凯麦拉医疗公司 | Irak4降解剂和其制备 |
| EP4472967A2 (en) | 2022-01-31 | 2024-12-11 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2023183377A1 (en) | 2022-03-23 | 2023-09-28 | Rigel Pharmaceuticals, Inc. | Pyrimid-2-yl-pyrazole compounds as irak inhibitors |
| CN118978528A (zh) * | 2024-08-02 | 2024-11-19 | 上海信诺维生物医药有限公司 | 一种irak4激酶抑制剂 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1937459A1 (de) * | 1968-08-02 | 1970-02-05 | Ciba Geigy | Neue Pyrimidinderivate und Verfahren zu ihrer Herstellung |
| CA2365578A1 (en) | 1999-03-30 | 2000-10-12 | Seiichi Uchida | Thienopyrimidine compounds and salts thereof and process for the preparation of the same |
| US6297238B1 (en) | 1999-04-06 | 2001-10-02 | Basf Aktiengesellschaft | Therapeutic agents |
| JP2005503345A (ja) * | 2001-04-30 | 2005-02-03 | バイエル・コーポレーシヨン | 新規な４−アミノ−５，６−置換チオフェノ［２，３−ｄ］ピリミジン |
| WO2003057149A2 (en) | 2001-12-28 | 2003-07-17 | Bayer Corporation | 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones |
| US20030225098A1 (en) | 2002-03-21 | 2003-12-04 | Hirst Gavin C. | Kinase inhibitors |
| US7199119B2 (en) | 2002-10-31 | 2007-04-03 | Amgen Inc. | Antiinflammation agents |
| JP2006522124A (ja) * | 2003-04-03 | 2006-09-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用な組成物 |
| WO2006010567A1 (de) | 2004-07-23 | 2006-02-02 | Curacyte Discovery Gmbh | INHIBITOREN DER PHOSPHODIESTERASE 4 UND TNFα-FREISETZUNG |
| EP1899353A1 (en) * | 2005-06-22 | 2008-03-19 | DeveloGen Aktiengesellschaft | Thienopyrimidines for pharmaceutical compositions |
| CA2668997C (en) | 2006-11-09 | 2012-10-09 | Ardea Biosciences, Inc. | 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors |
| US20100227853A1 (en) * | 2008-04-18 | 2010-09-09 | Trustees Of Boston College | Inhibitors of cyclic amp phosphodiesterases |
| CA2725416A1 (en) * | 2008-05-12 | 2009-11-19 | Amnestix, Inc. | Compounds for improving learning and memory |
| MX2011002263A (es) | 2008-09-10 | 2011-05-23 | Kalypsys Inc | Aminopirimidinas como inhibidores de receptores de histamina para el tratamiento de enfermedades. |
| EP2473054B1 (en) * | 2009-09-04 | 2017-06-14 | The Regents of the University of Michigan | Compositions and methods for treatment of leukemia |
| JP2012254939A (ja) * | 2009-10-07 | 2012-12-27 | Astellas Pharma Inc | オキサゾール化合物 |
| WO2011072127A1 (en) * | 2009-12-10 | 2011-06-16 | The University Of North Carolina At Chapel Hill | Selective beta-glucuronidase inhibitors as a treatment for side effects of camptothecin antineoplastic agents |
| CA2802641C (en) | 2010-07-13 | 2019-03-12 | Nidhi Arora | Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators |
| AU2011281015B2 (en) | 2010-07-23 | 2015-09-24 | President And Fellows Of Harvard College | Tricyclic proteasome activity enhancing compounds |
| EP3239154A1 (en) * | 2011-01-10 | 2017-11-01 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| EP3048106B1 (en) * | 2011-11-23 | 2019-11-06 | Cancer Research Technology Limited | Thienopyrimidine as inhibitors of atypical protein kinase c |
| WO2013106535A1 (en) | 2012-01-10 | 2013-07-18 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| JP2015528801A (ja) | 2012-07-11 | 2015-10-01 | ニンバス アイリス， インコーポレイテッド | Ｉｒａｋ阻害剤およびその使用 |
| EP2872144A4 (en) | 2012-07-11 | 2015-12-02 | Nimbus Iris Inc | IRAQ INHIBITOR AND USES THEREOF |
| US20140018361A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
-
2013
- 2013-01-10 WO PCT/US2013/020981 patent/WO2013106535A1/en not_active Ceased
- 2013-01-10 CA CA2863259A patent/CA2863259A1/en not_active Abandoned
- 2013-01-10 AU AU2013207972A patent/AU2013207972B2/en not_active Ceased
- 2013-01-10 CN CN201380013538.XA patent/CN104582705A/zh active Pending
- 2013-01-10 EP EP13735863.6A patent/EP2802330A4/en not_active Withdrawn
- 2013-01-10 BR BR112014017021A patent/BR112014017021A8/pt not_active IP Right Cessation
- 2013-01-10 US US13/738,410 patent/US9212190B2/en not_active Expired - Fee Related
- 2013-01-10 HK HK15110420.2A patent/HK1209632A1/xx unknown
- 2013-01-10 TW TW106101765A patent/TW201728592A/zh unknown
- 2013-01-10 JP JP2014552290A patent/JP6126131B2/ja active Active
- 2013-01-10 TW TW102101029A patent/TWI589579B/zh not_active IP Right Cessation
-
2015
- 2015-10-20 US US14/887,764 patent/US20160193216A1/en not_active Abandoned
-
2016
- 2016-10-14 JP JP2016203006A patent/JP2017008110A/ja active Pending
-
2017
- 2017-09-14 AU AU2017228639A patent/AU2017228639A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015503618A5 (enExample) | ||
| JP2015528801A5 (enExample) | ||
| JP2016531870A5 (enExample) | ||
| RU2016140870A (ru) | Ингибиторы irak и их применения | |
| RU2016110852A (ru) | Ингибиторы irak и их применения | |
| ES2975436T3 (es) | Enantiómeros (R) y (S) de n-(5-(3-hidroxipirrolidin-1-il)-2-morfolinooxazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4- il)oxazol-carboxamida como inhibidores de IRAK4 para el tratamiento del cáncer | |
| IL303987A (en) | IRAK joints and their uses | |
| JPWO2020113233A5 (enExample) | ||
| JP2017505337A5 (enExample) | ||
| JP2017502088A5 (enExample) | ||
| TWI827016B (zh) | 吡啶衍生物及其在醫藥上的應用 | |
| ES2930585T3 (es) | Inhibidores de TYK2 y usos de los mismos | |
| CA3086763A1 (en) | Irak degraders and uses thereof | |
| JP2017518348A5 (enExample) | ||
| AU2011241420B2 (en) | Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders | |
| JP2013504325A5 (enExample) | ||
| SA515360627B1 (ar) | مشتقات بيرازولو - بيريميدين نشطة علاجيا | |
| CA3040286A1 (en) | Tyk2 inhibitors and uses thereof | |
| PT2099797E (pt) | Compostos e composições como inibidores de proteína-quinase | |
| BRPI0908573A2 (pt) | inibidores da atividade de proteÍna tirosina quinase | |
| AU2011241420A1 (en) | Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders | |
| AU2012366148A1 (en) | 1,5-naphthyridine derivatives and melk inhibitors containing the same | |
| BR112014017735B1 (pt) | Compostos derivados de amida heterocíclicos como antagonistas do receptor de p2x7, composição farmacêutica, e, uso de um composto | |
| AU2020209789A1 (en) | Pyrrolopyrimidine derivative, and pharmaceutical composition for preventing or treating protein kinase-related disease comprising same as active ingredient | |
| AU2015274285C1 (en) | Pyrimidine compounds and methods using the same |